Class of medications: Dipeptidyl peptidase-4 (DPP-4) inhibitors
Weight neutral with low risk of hypoglycemia.
Demonstrates a statistically significant and clinically meaningful improvement in glycemic control.
More efficacious and have a better safety profile than acarbose and sulfonylurea.
Efficiently lowers FPG (fasting plasma glucose) and PPG (Postprandial glucose levels in combination therapy with metformin.
Become a PCD Pharma Franchise Owner
Start your own PCD Pharma Franchise in your region by becoming a partner with a Trusted PCD Pharma Franchise Partner. Apply now and our expert team will reach out to you!
[wpforms id=”3367″]
After downloading this form you will receive our product list.